Natural history of spinal cord compression stage AFMS3 in infants with achondroplasia: retrospective cohort study.

Magnetic Resonance Imaging Neuropathology Neurosurgery

Journal

Archives of disease in childhood
ISSN: 1468-2044
Titre abrégé: Arch Dis Child
Pays: England
ID NLM: 0372434

Informations de publication

Date de publication:
22 Aug 2024
Historique:
received: 19 02 2024
accepted: 08 08 2024
medline: 23 8 2024
pubmed: 23 8 2024
entrez: 22 8 2024
Statut: aheadofprint

Résumé

Foramen magnum stenosis (FMS) is a common, serious complication of achondroplasia in infancy and associated with sudden infant death. The Achondroplasia Foramen Magnum Score (AFMS; 0-4) is used to classify the severity of stenosis to inform appropriate neurosurgical management. Infants with AFMS4 are referred for neurosurgery, while well children with AFMS3 undergo repeat MRI routinely after 12 months.As the natural history of children with AFMS3 is currently unclear, the objective was to review follow-up MRI scans of infants initially classified as AFMS3 to define more clearly the evolution of this degree of stenosis. This retrospective cohort study, from two tertiary centres, included infants with a confirmed diagnosis of achondroplasia and AFMS3 on initial MRI who subsequently underwent repeat MRI or proceeded straight to neurosurgery. Twenty-two cases satisfied the inclusion criteria. Mean age in months was 6.23 (SD±3.82) and 17.95 (SD±7.68) at baseline and follow-up scans, respectively. Follow-up MRI showed no change in 23% (N=5), improvement in 36% (N=8) to either AFMS1 (N=5) or AFMS2 (N=3). There was progression in 41% to AFMS4 (N=8). One case had neurosurgey without follow-up MRI (N=1). These results support MRI screening for FMS in infants with achondroplasia. Furthermore, infants with AFMS3 should undergo follow-up MRI as over 40% progress prompting neurosurgical intervention. There is currently no consensus on frequency or timing of screening for AFMS3 in achondroplasia; however, we suggest that guidance for follow-up imaging is modified to 6 months to detect progression earlier in this at-risk cohort.

Sections du résumé

BACKGROUND AND OBJECTIVE OBJECTIVE
Foramen magnum stenosis (FMS) is a common, serious complication of achondroplasia in infancy and associated with sudden infant death. The Achondroplasia Foramen Magnum Score (AFMS; 0-4) is used to classify the severity of stenosis to inform appropriate neurosurgical management. Infants with AFMS4 are referred for neurosurgery, while well children with AFMS3 undergo repeat MRI routinely after 12 months.As the natural history of children with AFMS3 is currently unclear, the objective was to review follow-up MRI scans of infants initially classified as AFMS3 to define more clearly the evolution of this degree of stenosis.
DESIGN METHODS
This retrospective cohort study, from two tertiary centres, included infants with a confirmed diagnosis of achondroplasia and AFMS3 on initial MRI who subsequently underwent repeat MRI or proceeded straight to neurosurgery.
RESULTS RESULTS
Twenty-two cases satisfied the inclusion criteria. Mean age in months was 6.23 (SD±3.82) and 17.95 (SD±7.68) at baseline and follow-up scans, respectively. Follow-up MRI showed no change in 23% (N=5), improvement in 36% (N=8) to either AFMS1 (N=5) or AFMS2 (N=3). There was progression in 41% to AFMS4 (N=8). One case had neurosurgey without follow-up MRI (N=1).
CONCLUSIONS CONCLUSIONS
These results support MRI screening for FMS in infants with achondroplasia. Furthermore, infants with AFMS3 should undergo follow-up MRI as over 40% progress prompting neurosurgical intervention. There is currently no consensus on frequency or timing of screening for AFMS3 in achondroplasia; however, we suggest that guidance for follow-up imaging is modified to 6 months to detect progression earlier in this at-risk cohort.

Identifiants

pubmed: 39174296
pii: archdischild-2024-327035
doi: 10.1136/archdischild-2024-327035
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Moira Shang-Mei Cheung (MS)

Endocrinology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK moira.cheung@gosh.nhs.uk.

Alessandra Cocca (A)

Evelina London Children's Hospital, London, UK.

Charlotte H Harvey (CH)

Evelina London Children's Hospital, London, UK.

Connor Stephen S Brett (CSS)

Evelina London Children's Hospital, London, UK.

Amaka C Offiah (AC)

Reader & Honorary Consultant Paediatric Radiologist, Academic Unit of Child Health, University of Sheffield, Sheffield, UK.

Stephanie Borg (S)

Sheffield Children's NHS Foundation Trust, Sheffield, UK.

Nathan Jenko (N)

Sheffield Children's NHS Foundation Trust, Sheffield, UK.

Felice D'Arco (F)

Evelina London Children's Hospital, London, UK.
Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Dominic Thompson (D)

Department of Paediatric Neurosurgery, Great Ormond Street Hospital, London, UK.

Classifications MeSH